New developments for antibody-drug conjugate-based therapeutic approaches

Published on Jun 1, 2016in Current Opinion in Immunology7.29
· DOI :10.1016/J.COI.2016.02.008
Bart De Goeij7
Estimated H-index: 7
John M. Lambert52
Estimated H-index: 52
(ImmunoGen, Inc.)
The clinical success of Adcetris ® (brentuximab vedotin) and Kadcyla ® (ado-trastuzumab emtansine) has sparked clinical development of novel ADCs. These powerful anti-cancer agents are designed to allow specific targeting of highly potent cytotoxic agents to tumor cells while sparing healthy tissues. Despite the use of tumor-specific antibodies, the emerging clinical data with ADCs indicates that adverse effects frequently occur before ADCs have reached their optimal therapeutic dose, resulting in a relatively narrow therapeutic window. This review summarizes the therapeutic window of ADCs currently in clinical development, along with some strategies that may help to widen the window.
📖 Papers frequently viewed together
190 Citations
726 Citations
1,963 Citations
#1Watkins M Krystal (ImmunoGen, Inc.)H-Index: 1
#2Russell Walker (ImmunoGen, Inc.)H-Index: 3
Last. Angela Romanelli (ImmunoGen, Inc.)H-Index: 4
view all 6 authors...
IMGN779 is a CD33-targeting ADC consisting of a humanized anti-CD33 antibody, Z4681A, conjugated to DGN462, a novel DNA-alkylating agent, through a cleavable disulfide linker, sulfo-SPDB. CD33 is broadly expressed on leukemic blasts of patients with AML, making it a promising target for AML therapy. DGN462 is a member of the novel IGN class of DNA-acting cytotoxic agents, that consists of an indolino-benzodiazepine dimer containing a mono-imine moiety. Potent killing of AML tumor cells by DGN462...
13 CitationsSource
#1Philipp Müller (University of Basel)H-Index: 15
#2Matthias Kreuzaler (University of Basel)H-Index: 7
Last. Alfred Zippelius (University of Basel)H-Index: 47
view all 15 authors...
Targeted drug delivery with antibody-drug conjugates such as the HER2-directed ado-trastuzumab emtansine (T-DM1) has emerged as a powerful strategy for cancer therapy. We show that T-DM1 is particularly effective in eliciting antitumor immunity in patients with early breast cancer (WSG-ADAPT trial) and in a HER2-expressing orthotopic tumor model. In the latter, despite primary resistance to immunotherapy, combined treatment with T-DM1 and anti–CTLA-4/PD-1 (cytotoxic T lymphocyte–associated prote...
148 CitationsSource
The high-grade pulmonary neuroendocrine tumors, small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), remain among the most deadly malignancies. Therapies that effectively target and kill tumor-initiating cells (TICs) in these cancers should translate to improved patient survival. Patient-derived xenograft (PDX) tumors serve as excellent models to study tumor biology and characterize TICs. Increased expression of delta-like 3 (DLL3) was discovered in SCLC and LCNEC PDX t...
281 CitationsSource
#1Maria Corinna Palanca-Wessels (Fred Hutchinson Cancer Research Center)H-Index: 15
#2Myron S. Czuczman (Roswell Park Cancer Institute)H-Index: 69
Last. Franck Morschhauser (Lille University of Science and Technology)H-Index: 63
view all 21 authors...
Summary Background Patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) have an unfavourable prognosis with few treatment options. Polatuzumab vedotin is an antibody–drug conjugate containing an anti-CD79B monoclonal antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E. We aimed to assess the safety and clinical activity of polatuzumab vedotin in relapsed or refractory B-cell NHL and chronic lymphocytic leukaemia (CLL). Methods In this phase 1, multic...
147 CitationsSource
#1Efrat Dotan (Fox Chase Cancer Center)H-Index: 20
#2Alexander Starodub (Indiana University Health)H-Index: 19
Last. David M. GoldenbergH-Index: 129
view all 13 authors...
2505 Background: Combination chemotherapies with 5-FU, irinotecan, oxaliplatin, anti-VEGF, and anti-EGFR agents have improved the outcome of mCRC pts. However, there is still an urgent need for better therapies to control this disease. IMMU-130 (labetuzumab govitecan), a conjugate of a humanized anti-CEACAM5 antibody, coupled site-specifically to SN-38 (7.6 moles SN-38/IgG) using a proprietary linker, is an attractive therapeutic option for mCRC pts. Methods: A phase I/II clinical trial (NCT0160...
23 CitationsSource
#1Denise A. Yardley (Sarah Cannon Research Institute)H-Index: 57
#2Michelle E. Melisko (UCSF: University of California, San Francisco)H-Index: 33
Last. Linda T. Vahdat (Cornell University)H-Index: 57
view all 18 authors...
TPS1110 Background: The internalizable transmembrane glycoprotein NMB (gpNMB) is overexpressed in 20% of BC, including 40% of TNBC (Yardley JCO, in press), where it is a poor prognostic marker (Rose CCR 2010). gpNMB enhances tumor invasion and metastasis and promotes angiogenesis in preclinical models. GV is a novel antibody drug conjugate targeting the potent cytotoxin monomethylauristatin E (MMAE) to gpNMB+ tumor cells. In a Phase I/II study (Bendell JCO, 2014) and the Phase II “EMERGE” study ...
5 CitationsSource
#1Ulrik LassenH-Index: 37
#2David S. Hong (University of Texas MD Anderson Cancer Center)H-Index: 79
Last. Johann S. de Bono (The Royal Marsden NHS Foundation Trust)H-Index: 124
view all 9 authors...
2570 Background: TF-ADC is an antibody drug conjugate composed of a TF-specific human IgG1 monoclonal antibody conjugated to a microtubule disrupting agent Monomethyl Auristatin E (MMAE). TF-ADC is presently being tested in an ongoing Phase I dose-escalation study (NCT02001623) in patients (pts) with locally advanced and/or metastatic solid tumors known to express TF. Methods: The primary study objective is to assess the tolerability of TF-ADC. In addition, maximum tolerated dose (MTD), pharmaco...
5 CitationsSource
#1John A. Thompson (Seattle Cancer Care Alliance)H-Index: 34
#2Robert J. Motzer (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 140
Last. Leonard M. ReynoH-Index: 21
view all 16 authors...
2503 Background: ENPP3 is expressed in greater than 90% of clear cell (CC) and 70% of papillary (PAP) RCC and represents an interesting target in this disease. Hybridoma-derived AGS-16M8F and CHO-d...
17 CitationsSource
#1Hui K Gan (Ludwig Institute for Cancer Research)H-Index: 34
#2Kyriakos P. Papadopoulos (Texas Oncology)H-Index: 52
Last. David A. Reardon (Harvard University)H-Index: 105
view all 20 authors...
2016 Background: GBM remains almost universally fatal and new therapies are needed. The epidermal growth factor receptor (EGFR) is a key oncogenic target. ABT-414, an antibody-drug conjugate with a toxic payload (monomethylauristatin F) targeted to activated EGFR, showed efficacy in preclinical models. We report the data of patients (pts) with recurrent GBM (Arms B + C) from an ongoing phase 1, open-label, 3-arm study (NCT01800695). Methods: Eligible pts ( ≥ 18 years) had recurrent supratentoria...
11 CitationsSource
#1Alexander Starodub (Indiana University Health)H-Index: 19
#2Allyson J. Ocean (Cornell University)H-Index: 20
Last. David M. GoldenbergH-Index: 129
view all 13 authors...
Purpose: Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2, a surface glycoprotein expressed on many epithelial tumors, for delivery of SN-38, the active metabolite of irinotecan. This Phase I trial evaluated this ADC as a potential therapeutic for pretreated patients with a variety of metastatic solid cancers. Experimental Design: Sacituzumab govitecan was administered on days 1 and 8 of 21-day cycles, with cycles repeated until dose-limiting toxicity or prog...
121 CitationsSource
Cited By154
Abstract null null In this paper, a methodology for the development of a multimodal chromatography process is presented that is aimed at removal of under-conjugated antibody-drug conjugate (ADC) species. Two ADCs are used as case studies: One ADC results from site-directed conjugation to inserted cysteine residues and has a drug-to-antibody ratio (DAR) of two, the other is the product of conjugation to interchain disulfide bonds with a DAR of eight. First, filter plate screening studies are desi...
#2Erik SchootenH-Index: 1
Last. Paul M.P. van Bergen en Henegouwen (UU: Utrecht University)H-Index: 53
view all 0 authors...
Antibody-drug conjugates (ADCs) are currently used for the targeted delivery of drugs to diseased cells, but intracellular drug delivery and therefore efficacy may be suboptimal because of the large size, slow internalization and ineffective intracellular trafficking of the antibody. Using a phage display method selecting internalizing phages only, we developed internalizing single domain antibodies (sdAbs) with high binding affinity to rat PDGFRβ, a receptor involved in different types of disea...
#1Kyohei Muguruma (TITech: Tokyo Institute of Technology)H-Index: 1
#1Kyohei Muguruma (UTokyo: University of Tokyo)
Last. Yoshio Hayashi (Tokyo University of Pharmacy and Life Sciences)H-Index: 27
view all 10 authors...
Immunoglobulin G (IgG)-binding peptides such as 15-IgBP are convenient tools for site-specific modification of antibodies and the preparation of homogeneous antibody-drug conjugates. A peptide such as 15-IgBP can be selectively crosslinked to the fragment crystallizable region of human IgG in an affinity-dependent manner via the e-amino group of Lys8. Previously, we found that the peptide 15-Lys8Leu has a high affinity (Kd = 8.19 nM) due to the presence of the γ-dimethyl group in Leu8. The prima...
view all 4 authors...
#1Nathan M. Kendsersky (Children's Hospital of Philadelphia)H-Index: 4
#2Jarrett M Lindsay (Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania)H-Index: 1
Last. John M. Maris (Children's Hospital of Philadelphia)H-Index: 104
view all 23 authors...
Purpose: Patients with relapsed pediatric solid malignancies have few therapeutic options, and many of these patients die of their disease. B7-H3 is an immune checkpoint protein encoded by the CD276 gene that is overexpressed in many pediatric cancers. Here, we investigate the activity of the B7-H3-targeting antibody-drug conjugate (ADC) m276-SL-PBD in pediatric solid malignancy patient-derived and cell line-derived xenograft (PDX and CDX) models. Experimental Design: B7-H3 expression was quanti...
2 CitationsSource
#1Joshua Z. Drago (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 5
#1Joshua Z. Drago (Cornell University)
Last. Sarat Chandarlapaty (Cornell University)H-Index: 51
view all 3 authors...
Nine different antibody–drug conjugates (ADCs) are currently approved as cancer treatments, with dozens more in preclinical and clinical development. The primary goal of ADCs is to improve the therapeutic index of antineoplastic agents by restricting their systemic delivery to cells that express the target antigen of interest. Advances in synthetic biochemistry have ushered in a new generation of ADCs, which promise to improve upon the tissue specificity and cytotoxicity of their predecessors. M...
4 CitationsSource
#1Trevor S. AndersonH-Index: 1
#2Amanda L. WoosterH-Index: 1
Last. Devin B. LoweH-Index: 13
view all 5 authors...
Melanoma continues to be an aggressive and deadly form of skin cancer while therapeutic options are continuously developing in an effort to provide long-term solutions for patients. Immunotherapeutic strategies incorporating antibody-drug conjugates (ADCs) have seen varied levels of success across tumor types and represent a promising approach for melanoma. This review will explore the successes of FDA-approved ADCs to date compared to the ongoing efforts of melanoma-targeting ADCs. The challeng...
#1Xinning Wang (Case Western Reserve University)H-Index: 14
#2Aditi Ashish Shirke (Case Western Reserve University)H-Index: 1
Last. James P. Basilion (Case Western Reserve University)H-Index: 32
view all 19 authors...
Metastatic castration-resistant prostate cancer poses a serious clinical problem with poor outcomes and remains a deadly disease. New targeted treatment options are urgently needed. PSMA is highly expressed in prostate cancer and has been an attractive biomarker for the treatment of prostate cancer. In this study, we explored the feasibility of targeted delivery of an antimitotic drug, monomethyl auristatin E (MMAE), to tumor tissue using a small-molecule based PSMA lig-and. With the aid of Cy5....
#1Tatsuya IshiguroH-Index: 11
#2Takayuki EnomotoH-Index: 62
#1Xianglong Yu (Beijing University of Chinese Medicine)H-Index: 2
#2Huichao Wu (Beijing University of Chinese Medicine)H-Index: 6
Last. Yang Lu (Beijing University of Chinese Medicine)H-Index: 12
view all 9 authors...
AbstractPurpose: Maytansine (DM1) is a potent anticancer drug and limited in clinical application due to its poor water solubility and toxic side effects. Zein is widely used in nano drug delivery ...
4 CitationsSource